Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for use in clinical research. If granted appropriate regulatory approvals, this could eventually be used as a treatment for clients in psychedelic-assisted therapy.

Numinus strives to be at the cutting edge of psychedelic-assisted therapies that are both innovative and safe. Numinus VP, Scientific Research, Innovation & Laboratory Operations Sharan Sidhu said the Numinus team developed the Psilocybe tea bag with scientific precision in mind.

The VP stated that the company’s best-in-class team and resources allow Numinus to control the full production process, from growth to finished product manufacturing, to deliver a fully standardized product.

History of Psilocybe Psiloycybin Tea Bags

The study of the tea bag focused on developing processing and procedure to deliver 25mg per dose using Numinus’ verified Psilocybe cubensis strains.

Psilocybe cubensis is a species of psychedelic mushroom with primary active compounds psilocybin and psilocin. The most popular strain of psilocybin is known as Stropharia cubensis. It belongs to the fungus family Hymenogastraceae and is the most well-known psilocybin mushroom due to its wide presence and simple cultivation.

Numinus’ Psilocybe tea bag will be studied in a phase 1 trial of people receiving experiential training for psilocybin-assisted therapy, to use it in Numinus’ research, including trials at Cedar Clinical Research, which is Numinus’ clinical trial management division.

About Numinus Wellness

Numinus Wellness is s mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies. The company helps people recover from mental health difficulties and live a healthy life by developing and delivering innovative mental health care as well as providing safe, evidence-based psychedelic-assisted therapies.

The Numinus model, which includes psychedelic production, research, and treatment at clinics, is leading the charge for a shift in emphasis from treating symptoms of depression, anxiety, trauma, pain, and substance addiction to healing rather than managing them.

Psilocybe Psiloycybin Tea Bag Health Canada Approval

Health Canada has also received an application to include the product on the psilocybin supplier list for the federal Special Access Program. If approved, healthcare providers would be able to offer psilocybin-assisted therapy, among other psychedelic-assisted therapies, to patients with a demonstrable need.

Chief Scientific Officer Dr. Paul Thielking pointed out the benefits of the standardized dose mushroom tea bags.

“Numinus recognizes that solid therapeutic products, such as whole mushrooms or pills, might be unappealing or difficult to use by certain populations, such as some people receiving palliative care for serious illnesses. This new product is part of our commitment to increasing accessibility to psychedelic-assisted therapies for those in need while contributing to the growing research that suggests psilocybin use in combination with therapy may be highly effective for treating mental health disorders.”

Leave a Reply

Your email address will not be published.

Previous Story

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

Next Story

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment